CSPC Pharmaceutical Group (CHJTF) Price & Analysis

Compare

28 Followers

CHJTF Stock Chart & Stats

$1.39

>-$0.01(-0.77%)

At close: Dec 23 4:00 PM EST

$1.39

>-$0.01(-0.77%)

Day’s Range― - ―

52-Week Range$0.55 - $1.41

Previous CloseN/A

Volume389.00

Average Volume (3M)14.41K

Market Cap

$15.42B

Enterprise Value$94.92B

Total Cash (Recent Filing)$10.63B

Total Debt (Recent Filing)$495.00M

Price to Earnings (P/E)30.0

Beta0.26

Next Earnings

Mar 25, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend Yield3.2%

Share Statistics

EPS (TTM)0.01

Shares Outstanding11,522,452,000

10 Day Avg. Volume2,182

30 Day Avg. Volume14,414

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)1.63

Price to Sales (P/S)1.90

P/FCF Ratio30.23

Enterprise Value/Market Cap6.15

Enterprise Value/Revenue3.49

Enterprise Value/Gross Profit5.23

Enterprise Value/Ebitda14.13

Forecast

1Y Price Target

$1.47

Price Target Upside5.76% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering18

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline ProgressEarly clinical activity for SYS6010 in heavily pretreated, treatment-resistant lung cancer patients shows promising signals that could boost the asset's valuation and increase partner interest for further development.

Out-licensing Revenue StreamA track record of multiple out-licensing agreements across diverse assets supports a recurring business development income stream that can monetize discoveries without bearing late-stage commercialization risk.

Strategic CollaborationStrategic collaboration with a global pharmaceutical partner validates CSPC's AI-driven drug discovery and sustained-release peptide platforms and could attract partner-funded development and licensing opportunities that expand non-dilutive capital sources.

Bears Say

Commercial Execution RiskSustaining revenue momentum appears challenged by underlying sales weakness, highlighting execution and market-share risks that could slow recovery without stronger product-level performance.

Core Sales DeclineCore revenue excluding business development income declined 19% year-over-year, indicating weakening underlying sales momentum that could reduce top-line stability and investor confidence.

Profitability PressureThe drop in core sales may exert pressure on operating margins and make recent improvements in selling expense insufficient to sustain long-term earnings growth.

CSPC Pharmaceutical Group News

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group has secured drug...

12d ago

CSPC Strikes US$1.2 Billion AstraZeneca Deal for Long-Acting Peptide and Obesity Drugs

CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an update. CSPC Pharmaceutical Group has entered into a strategic...

15d ago

CSPC Wins China’s First Clinical Green Light for In Vivo CAR-T Therapy

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group has received approval from China’s...

16d ago

CSPC Pharmaceutical Grants 46.5 Million Restricted Shares to 727 Employees

CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an update. CSPC Pharmaceutical Group has granted 46,462,500 restricted shares,...

22d ago

CSPC Innovation Warns of 2025 Loss as R&D Surge Accelerates Drug Pipeline

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Innovation Pharmaceutical Co., a subsidiary of CSPC...

30d ago

CSPC Wins U.S. FDA Nod for Trial of Novel Hypertension Drug SYH2072

An announcement from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group has received approval...

1M ago

CSPC Wins NMPA Acceptance for Prusogliptin–Metformin Combo in Diabetes Push

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group has had its...

1M ago

CSPC Wins China Trial Green Light for First Inhaled Nintedanib for Pulmonary Fibrosis

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group has received approval from China’s...

1M ago

CSPC Wins China Clinical Trial Nod for Next-Generation Obesity Drug SYH2069

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group has reported that its internally...

2M ago

CSPC Wins China Trial Nod for First-in-Class Triple Diabetes Combination Therapy

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group has received approval from China’s...

2M ago

CHJTF FAQ

What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?

CSPC Pharmaceutical Group Limited lowest stock price was $0.55 and its highest was $1.41 in the past 12 months.

What is CSPC Pharmaceutical Group Limited’s market cap?

CSPC Pharmaceutical Group Limited’s market cap is $15.42B.

When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?

CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Mar 25, 2026 which is in 39 days.

How were CSPC Pharmaceutical Group Limited’s earnings last quarter?

CSPC Pharmaceutical Group Limited released its earnings results on Nov 20, 2025. The company reported $0.012 earnings per share for the quarter, missing the consensus estimate of $0.017 by -$0.005.

Is CSPC Pharmaceutical Group Limited overvalued?

According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CSPC Pharmaceutical Group Limited pay dividends?

CSPC Pharmaceutical Group Limited pays a Semiannually dividend of $0.018 which represents an annual dividend yield of 3.2%. See more information on CSPC Pharmaceutical Group Limited dividends here

What is CSPC Pharmaceutical Group Limited’s EPS estimate?

CSPC Pharmaceutical Group Limited’s EPS estimate is 0.02.

How many shares outstanding does CSPC Pharmaceutical Group Limited have?

CSPC Pharmaceutical Group Limited has 11,522,452,000 shares outstanding.

What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?

CSPC Pharmaceutical Group Limited reported an EPS of $0.012 in its last earnings report, missing expectations of $0.017. Following the earnings report the stock price went up 0.103%.

Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?

Currently, no hedge funds are holding shares in CHJTF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CSPC Pharmaceutical Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

11.30%

Trailing 12-Months

Asset Growth

-2.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

CSPC Pharmaceutical Group (CHJTF) Earnings & Revenues

Historic Earnings Reports

CHJTF Stock 12 Month Forecast

Average Price Target

$1.47

▲(5.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.462999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8444568,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.2,1.297153769230769,1.3943075384615384,1.4914613076923076,1.588615076923077,1.685768846153846,1.7829226153846154,1.8800763846153845,1.9772301538461536,2.074383923076923,2.1715376923076923,2.2686914615384612,2.3658452307692306,{"y":2.462999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.2,1.2207692307692308,1.2415384615384615,1.2623076923076924,1.283076923076923,1.3038461538461539,1.3246153846153845,1.3453846153846154,1.366153846153846,1.386923076923077,1.4076923076923076,1.4284615384615384,1.449230769230769,{"y":1.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.2,1.172650523076923,1.1453010461538462,1.117951569230769,1.0906020923076922,1.0632526153846154,1.0359031384615385,1.0085536615384616,0.9812041846153846,0.9538547076923076,0.9265052307692307,0.8991557538461539,0.871806276923077,{"y":0.8444568,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.563,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.585,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.544,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.973,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.239,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.254,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.081,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.989,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.005,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.961,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >